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Background: Fabry disease (FD) is a multisystemic disorder with typical neurological manifestations such as stroke
and small fiber neuropathy (SFN), caused by mutations of the alpha-galactosidase A (GLA) gene. We analyzed 15
patients carrying the GLA haplotype -10C>T [rs2071225], IVS2-81_-77delCAGCC [rs5903184], IVS4-16A>G [rs2071397],
and IVS6-22C>T [rs2071228] for potential neurological manifestations.
Methods and results: Patients were retrospectively analyzed for stroke, transient ischemic attack (TIA), white matter
lesions (WML) and SFN with neuropathic pain. Functional impact of the haplotype was determined by molecular
genetic methods including real-time PCR, exon trapping, promoter deletion constructs and electrophoretic mobility
shift assays. Symptomatic -10T allele carriers suffered from stroke, TIA, WML, and SFN with neuropathic pain. Patients’
mean GLA mRNA expression level was reduced to ~70% (p < 0.0001) and a dose-dependent effect of the -10T allele on
GLA mRNA expression was observed in hemi/homozygous compared to heterozygous patients (p < 0.0001). Molecular
analyzes revealed that the -10T allele resulted in a reduced promoter activity and an altered transcription factor binding,
while a functional relevance of the co-segregated intronic variants was excluded by exon trapping.
Conclusions: Based on this complementary approach of clinical observation and functional testing, we conclude that
the GLA -10T allele could be causal for the observed neurological manifestations. Future studies are needed to clarify
whether affected patients benefit from GLA enzyme replacement therapy for end-organ damage prevention.
Keywords: Neuropathic pain, Stroke, Cerebrovascular disease, Fabry disease, Gene expression regulationBackground
A deficiency of alpha-galactosidase A (GLA, E.C.3.2.1.22)
leads to Fabry disease (FD), an X-linked lysosomal storage
disorder. The impaired glycosphingolipid catabolism pro-
vokes progressive accumulation of glycosphingolipids,
mainly globotriaosylceramide (Gb3), resulting in a mul-
tisystemic disease [1]. Progressive accumulation of Gb3
leads to macro- and microangiopathic alterations with
transient ischemic attack (TIA), stroke, myocardial infarc-
tion, life-threatening cardiac arrhythmia and end-stage
renal disease resulting in a 10–15 years reduced life-span* Correspondence: Eva.Brand@ukmuenster.de
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article, unless otherwise stated.without adequate therapy [2]. First symptoms of FD
include neuropathic pain attacks due to small fiber neur-
opathy (SFN) [2,3]. FD routine diagnosis is based on the
described typical clinical picture, decreased enzymatic
GLA activities and analysis of coding GLA variants.
The non-coding GLA -10T allele (rs2071225), located
within the 5′-untranslated region (UTR), has been
suggested to be associated with decreased GLA protein
expression [4], although the -10T allele co-segregates in
a haplotype background with three additional intronic
variants (IVS281_-77delCAGCC [rs5903184], IVS4-16A>G
[rs2071397], and IVS6-22C>T [rs2071228]) [5,6]. This
haplotype has been reported in patients with SFN of
unknown etiology as well as in patients with classical
FD [5,6]. Until now, the functional role of the -10T allele
and the co-segregating intronic variants remains uncleartral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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peptide sequences and possibly modifying protein struc-
ture and function, the consequences of intronic sequences
are not predictable. As shown for the mid-intronic GLA
mutation IVS4+919A>G, intronic variations can affect the
process of alternative splicing [7,8]. Due to this mutation,
a weak splice site can be converted, resulting in an
increased recognition and the insertion of an intronic
sequence into the GLA transcript leading to a cardiac
phenotype of FD [7,8].
In general, efficient splicing of pre-mRNAs depends
on conserved intronic sequences. The efficiency of spli-
cing can further be modified by splicing enhancers or
suppressors, sequences located within exons and introns.
As opposed to the well-defined consensus splice sites,
these elements are not completely characterized. Thus, a
prediction whether a genomic variation affects splicing
is not possible yet and the impact has to be confirmed
experimentally [9].
In the current work, we retrospectively analyzed 15 -10T
allele carrying patients from our database after presenta-
tion of a symptomatic index patient with a neurological
phenotype. Our complementary approach included clinical
data and detailed molecular functional analyses.
Methods
Patients
The study retrospectively analyzed patients with the
GLA -10T haplotype who presented at the Fabry centerFigure 1 Presentation of the retrospective study design. Between 07/2
University Hospital Muenster with Fabry-typical neurological manifestations
unknown etiology. Out of 86 patients 49 had classical Fabry disease-causin
patients had no GLA mutation. Two asymptomatic patients were identified
allele carriers and retrospectively analyzed clinical data.of the University Hospital of Muenster (IFAZ) between
07/2011 and 12/2013 (Figure 1). All patients had been
examined by neurologists, cardiologists and nephrolo-
gists at the Fabry center. Neuropathic pain was diagnosed
according to the revised criteria of the Neuropathic Pain
Special Interest Group of the International Association for
the Study of Pain (NeuPSIG) [10]. All investigations were
performed after approval of the Medical Association of
Westfalian Lippe and the Ethical Committee of the
Medical Faculty of the University of Muenster (project-no.:
2011-347-f, date of report: 07.07.2011). Written informed
consent of patients was obtained for molecular analysis
and publication.GLA activity, lyso-Gb3 measurements and GLA sequencing
GLA activity was determined using 4-methylumbelliferyl-α-
D-galactopyranoside (Santa Cruz Biotechnology, Heidelberg,
Germany), as described previously [11]. N-acetylgalactosa-
mine (Santa Cruz Biotechnology) was used as specific
inhibitor of endogenous α-Galactosidase B activity [12].
GLA enzyme activity was determined as nanomoles
(nmol) of substrate hydrolyzed per hour (h) per mg
protein. For lyso-Gb3, lysoCeramide was used as reference
(Matreya LLC, Pleasant Gap, USA) and D5-fluticasone
propionate (EJY Tech, Inc., Rockville, USA) served as
internal standard. Genomic DNA (isolated from leukocytes)
had been sequenced for GLA exons and 30–50 bp of adja-
cent introns.011 and 12/2013 86 new patients presented at the Fabry center of the
such as small fiber neuropathy with neuropathic pain, or stroke/TIA of
g mutations, 12 patients were symptomatic -10T allele carriers and 25
by family screening. We analyzed GLA expression in all detected -10T
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Cerebral lesion volume on axial fluid attenuated inversion
recovery sequences was determined semi-automatically by
outlining the peripheral borders of white matter lesions
(WML). Lesions were marked and borders were set by
local thresholding using a custom-tailored software based
on Analysis-software (Brain Imaging Resource, Mayo
Clinic, Rochester, USA). WML were additionally rated on
a 3-point scale according to the well-established score of
Fazekas [13].
Skin biopsy histology
A 3 mm skin punch biopsy was obtained from the right
distal calf and fixed in Zamboni solution. Forty μm
cryostat sections were stained with a polyclonal rabbit
anti-PGP9.5 antiserum (Ultraclone, Yarmouth, UK) as
described previously [14]. Immunoreactivity was visualized
using Alexa Fluor 488 (Invitrogen, Darmstadt, Germany)
labeled goat anti-rabbit secondary antibodies. Intra-
epidermal nerve fiber density (IENFD) was determined
using the method described by Lauria et al. [15], count-
ing only nerve fibers crossing the epidermal basement
membrane and excluding nerve fragments in the
epidermis that did not cross the basement membrane.
Specimen length was determined using the scale bar in
the microscope eyepiece calibrated with a standardized
scale bar slide. The normal value references were >9
fibers/mm based on published [15] and own control
subjects (n = 66) normative data. In addition, axons
showing focal swellings of >1.5 μm in diameter were
counted. Such swellings are supposed to indicate dis-
turbances in axonal transport [16].
Quantitative sensory testing
All patients underwent the QST protocol as developed
by the German Research Network on Neuropathic Pain
[17,18]. This protocol encompasses the following items:
cold detection threshold (CDT), warm detection threshold
(WDT), cold pain threshold (CPT), heat pain threshold
(HPT), thermal sensory limen (TSL), the presence of
paradoxical heat sensations (PHS), mechanical detection
thresholds (MDT) to von Frey filaments, vibration sensa-
tion (VDT) making use of a 64-Hz tuning fork, mechan-
ical pain thresholds to pinprick stimuli (MPT) and blunt
pressure (PPT), stimulus–response–functions for pinprick
(MPS) and dynamic mechanical allodynia (DMA), and
pain summation (wind-up ratio, WUR) using repetitive
pinprick stimulation. The tests were all performed at the
dorsum of the left hand and the dorsum of the right foot.
The thermal tests were performed using a TSA 2001-II
(Medoc, Israel). For individual analysis, each patient’s
values were compared with published reference values
[17]. Based on the log transformed raw values for each
QST item, a Z-score sensory profile was calculated asfollows: Z-score = (value of the subject – mean value of
controls)/standard deviation of controls. Negative Z-
scores indicate loss of sensation, positive Z-scores indicate
gain of sensation.
Transmission electron microscopy
For electron microscopy specimens were fixed in
Karnovsky’s fixative, postfixed in 1% osmium tetroxide
and embedded in Epon. Ultrathin sections were coun-
terstained with uranyl acetate and lead citrate and
examined in a Philips CM10 electron microscope.
Real-time PCR analysis
Total RNA extraction from patients’ peripheral mono-
nuclear blood cells was performed using the NucleoSpin
RNA Blood Kit (Macherey-Nagel, Düren, Germany). Five
hundred ng of patients’ total RNA was reverse transcribed
using SuperScriptII Reverse Transcriptase (Invitrogen).
Relative GLA transcript levels (NM_000169.2) were an-
alyzed in duplicates using Power SYBR Green (Applied
Biosystem, Carlsbad, USA) on an Applied Biosystems 7500
Fast real-time PCR system. Glyceraldehyde 3-phosphate
dehydrogenase was used as endogenous reference control.
Oligonucleotides used for amplification are given in
Additional file 1: Table S2. Amplification standard curves
were generated by cDNA serial dilutions. Melting curve
analysis was used to assess PCR specificity. Relative ex-
pression level of GLA was analyzed using the 2−ΔΔCt
method [19]. The absence of non-specific amplification
was confirmed by agarose gel electrophoresis of PCR
amplicons. Real-time PCR has been repeated at least
twice.
Cell culture
Immortalized human kidney epithelial cells (IHKE) [20-22]
were maintained in Dulbecco’s modified Eagle’s medium/
Ham’s-F12 with 1% fetal calf serum (FCS; PAA, Cölbe,
Germany), 100 units/ml penicillin, 100 ng/ml streptomycin,
2 mmol/ml L-glutamine, 10 ml/l insulin-transferrin-sodium
selenite media supplement, 1.25 g/l NaHCO3, 55 mg/l
sodium pyruvate, 10 μg/l human epidermal growth factor
(all Sigma-Aldrich, Munich, Germany) and 15 mmol/l N-2-
hydroxyethylpiperazine-N-2-ethanesulfonic acid (Merck,
Darmstadt, Germany). The human vascular endothelial
cell line EA.hy926 was maintained in Dulbecco’s modified
Eagle’s medium with 10% FCS, 100 units/ml penicillin,
100 ng/ml streptomycin and 2 mmol/ml L-glutamine. The
monocytic cell line THP-1 was maintained in RPMI 1640,
10% FCS, 100 units/ml penicillin, 100 μg/ml streptomycin,
and 1x modified Eagle’s medium amino acid solution
(Sigma-Aldrich). Human SH-SY5Y neuroblastoma cells
were maintained in Dulbecco’s modified Eagle’s medium
with 20% FCS, 100 units/ml penicillin, 100 ng/ml strepto-
mycin and 2 mmol/ml L-glutamine. Cells were transfected
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which transcription is driven by a viral SV40-promoter,
served as control for transfection efficiency. For transcrip-
tion factor EB (TFEB) co-transfection assays, expression
vector pcDNA3.1(+) TFEB and GLA promoter deletion
constructs were transfected in a 3:1 ratio. Transfection
experiments were repeated at least twice.
Exon trapping assay
The influence of intronic GLA variants on splice events
was analyzed by use of the exon trapping vector pSPL3.
GLA exon 3 (IVS2-81_-77delCAGCC [rs5903184]), exon
5 (IVS4-16A>G [rs2071397]) and exon 7 (IVS6-22C>T
[rs2071228]) were PCR-amplified with approximately
250 bp flanking introns (wild-type and mutation), and
inserted into the pSPL3 vector. The intronic GLA variant
IVS4+919G>A served as a positive control [7,23]. Mini-
gene constructs were transfected into EA.hy926 and
SH-SY5Y cells using Nanofectin (PAA). Twenty-four hours
after transfection, RNA was extracted using NucleoSpin
RNAII (Machery-Nagel), and single-stranded cDNA was
synthesized (SuperScriptII Reverse Transcriptase, Invitro-
gen). PCR was performed using vector-specific primers
SD6 and SA2. Signals were analyzed on 2% agarose
gels. Identity of PCR amplicons was validated by direct
sequencing. Oligonucleotide sequences are given in
Additional file 1: Table S2.
Serial promoter deletion constructs
GLA serial promoter deletion constructs were generated
using the pGL3 reporter gene vector system (Promega,
Mannheim, Germany) based on the GLA translational
start site (NM_000169.2). Luciferase activities were deter-
mined using the luciferase assay kit (Promega) and a Sirius
luminometer (Berthold detection systems, Pforzheim,
Germany). The -10T allele was introduced by site-directed
mutagenesis. All vectors were sequenced to ensure se-
quence accuracy and identity. Oligonucleotide sequences
are given in Additional file 1: Table S2.
Chromatin immunoprecipitation (ChIP)
ChIP was performed as described previously [24,25]. A
Bioruptor (Diagenode, Liège, Belgium) was used for
DNA sonication until the chromatin had an average size
of 300–500 bp (≤45 min, 0.5 s interval, 200 W, 4°C).
ChIP was conducted using 3 μg of TFEB antibody
(TFEB-C6, #166736, Santa Cruz Biotechnology). ChIP
experiments were repeated twice. Oligonucleotides used
for amplification of precipitated chromatin are given in
Additional file 1: Table S2.
Electrophoretic mobility shift assay (EMSA)
Nuclear protein extracts of EA.hy926 cells were pre-
pared by a modified protocol [26]. Oligonucleotides forDNA probes containing position -10 of the GLA 5′-
UTR were 3′-biotinylated with biotin-16-ddUTP (Roche,
Mannheim, Germany) using terminal transferase (Roche).
Per reaction, 5 μg nuclear protein extracts were incubated
with 500 ng pre-sheared poly(dI•dC) (USB, Staufen,
Germany) as non-specific competitor and a 200-fold
molar excess of unlabeled oligonucleotides as specific
competitor. The EMSA shown is representative for at least
two experiments. Oligonucleotide sequences are given in
Additional file 1: Table S2.
Statistical analysis
Two-tailed student’s t-test was used for statistical analysis.
P-values <0.05 were considered as statistically significant.
Results
Symptomatic carriers of the minor -10T allele suffer from
neurological manifestations and show decreased GLA
mRNA expression levels
An index patient (patient #1) presented at the Fabry
center of the University Hospital of Muenster (IFAZ)
with severely impaired daily activity and reduced quality
of life due to neuropathic pain of the distal extremities
with “burning” hands and feet and physical weakness at
the age of 56 years (Tables 1 and 2, Additional file 1:
Table S1). She reported about first neuropathic pain
symptoms at the age of 40 years. In-depths clinical and
laboratory investigations revealed a SFN and widespread
periventricular to subcortical WML (Figure 2A-C). Left-
ventricular hypertrophy and diastolic ventricular dysfunc-
tion indicated cardiac involvement. A detailed laboratory
investigation and cerebrospinal fluid (CSF) analysis were
unrevealing. The patient had an unrevealing cardio-
vascular risk profile and no evidence of extracerebral
arteriopathy, vasculitis or other inflammatory disease.
Since further investigations revealed no evidence for
common causes of SFN, the patient was tested for FD.
Direct GLA sequencing revealed -10T heterozygosity in
the 5′-UTR in a haplotype with the three intronic variants
(IVS2-81_-77delCAGCC, IVS4-16A>G and IVS6-22C>T).
No other mutation within the GLA coding region or
exon-intron boundaries was found (Table 1, Additional
file 1: Table S1). Since several reports existed on -10T
heterozygosity and Fabry-typical manifestations [4-6]
we retrospectively analyzed additional 14 -10T allele
carriers (44.4 [12–72] years of age) from our database
(Figure 1, Tables 1 and 2, Additional file 1: Table S1).
Out of 15 -10T carriers 13 presented with neuropathic
pain (symptom onset: patients #3-7 and #9-11 in child-
hood; #2 at 20 and #8 at 40 years of age) and/or cerebro-
vascular manifestations such as WML, TIA or stroke
(Table 1). Blood count (including total leukocyte count),
renal and liver function tests as well as homocysteine level
and angiotensin-converting enzyme were normal. Serum
Table 1 Patients’ characteristics
Neurological manifestations WML characterization












[age of onset, years]
Localization FS V
[ml]
-10T carriers with neurological manifestations




Definite Before ERT: 10 Before ERT: 8 4.64† Abnormal WML, TIA [62] Periventricular
and subcortical
1 10.9
After ERT: 4 After ERT: 2
2 f 43 -10T/X Neuropathic pain, allodynia Definite 7 4 4.4† Abnormal - - - -
3 m 12 -10T/Y Neuropathic pain, chronic
headache
Definite 4 1 NA Abnormal - - - -
4 m 15 -10T/Y Neuropathic pain, autonomic
neuropathy (postprandial
gastrointestinal dysfunction)
Definite 6 3 NA Abnormal - - - -
5 f 46 -10T/X Neuropathic pain Probable 6 5 NA NA - - - -
6 f 53 -10T/X Neuropathic pain Probable 7 6 NA Normal - - - -
7 f 65 -10T/X Neuropathic pain, allodynia Definite 9 5 4.65† Abnormal TIA [64] - - -
8 f 49 -10T/X Neuropathic pain, chronic
headache




9 f 55 -10T/X Neuropathic pain Probable 10 8 13.4 Abnormal - - - -
10 f 54 -10T/-10T Neuropathic pain Definite 9 6 NA Abnormal TIA [52] - - -




12 m 52 -10T/Y None No pain 0 0 NA NA Stroke [48] - - -
13 m 35 -10T/Y None No pain 0 0 NA NA Stroke [34] - - -
-10T carriers without neurological manifestations
14 m 19 -10T/Y none No pain 0 0 NA Normal - - - -
15 m 33 -10T/Y none No pain 0 0 NA NA - - - -
†reduced intra-epidermal nerve fiber density (IENFD; <9 fibers/mm); f: female; m: male; WML: white matter lesions; TIA: transient ischemic attack; QST: quantitative sensory testing; NA: not available; +: according to the
Neuropathic Pain Special Interest Group (NeuPSIG); NRS: numeric rating scale (0–10 scale; 0: no pain, 10: worst possible pain); FS: Fazekas score: 0: no WML, 1: punctate foci of WML, 2: beginning confluence of foci of



















Table 2 Laboratory FD parameters






1* 2.67 0.88 0.68
2 3.09 0.87 1.08
3 0.91+ 0.57 0.46
4 1.76 0.52 0.63
5 2.12 0.69 0.20
6 2.00 NA 0.90
7 2.20 1.20 0.50
8 1.60 0.76 0.50
9 2.64 1.00 0.50
10 1.92 0.63 0.30
11 0.94+ 0.85 0.60
12 0.61+ 0.48 0.90
13 0.88+ NA 0.60
14 1.48 0.57 1.12
15 2.84 0.66 0.40
Reference values: GLA activity in leukocytes >33 nmol MU/h/mg protein; GLA
activity in dried blood spots >2.5 μmol/l/h. Lyso-Gb3 plasma <2.2 ng/ml; NA:
not available; FI: fold induction; FD: Fabry disease. *: index patient; +: reduced
GLA activity.
Figure 2 Magnetic resonance imaging (MRI) and small fiber neuropathy
inversion recovery (FLAIR) MRI of patient #1 showed multiple, punctuated wh
subcortical (red arrows and circles) without gadolinium enhancement. (D) Ski
epidermal nerve fibers (arrow). Scale bar = 20 μm. (E-F). The number of focal
bar = 10 μm. (G) Skin biopsy of a healthy control. Scale bar = 30 μm.
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glutamic acid decarboxylase, and onconeural antibodies
(anti-amphiphysin, anti-Ri, anti-Yo, anti-Hu, anti-CV2/
CRMP5, anti-Ma2/Ta, anti-NMDA, LGI-1, GAD) as well
as anti-cardiolipin immunoglobulin were all negative. A
screen for antibodies against extractable nuclear and
anti-nuclear antigens was also negative. No patient had
evidence of an inflammatory disease since serological
testing excluded borreliosis, syphilis and HIV-1 infection.
Cerebral MR-angiography was obtained in all patients
with WML and showed no evidence of vasculitis.
Sonography of the extracranial vessels were performed
in all patients with stroke/TIA or WML (patients #1;
#7; #8; #10-13) and showed no severe arteriopathy.
Further examination revealed no evidence for common
causes of SFN since blood glucose and hemoglobin A1c
levels, blood count including total leukocyte count, c-
reactive protein, thyroid and liver parameters, vitamins
B1, B6, B12 and homocysteine levels, serum protein
and immunoelectrophoresis were normal. CSF analyses
were obtained in patients #1, #2, #8, and #11-13 and
showed unrevealing results. Since CSF analyses were
not performed in all patients, we could not definitively
exclude inflammatory disease. However, no patient
fulfilled the diagnostic criteria of primary vasculitis of the
CNS or multiple sclerosis, regardless of CSF analysisdiagnosis by PGP9.5 immunofluorescence. (A-C) Fluid attenuated
ite matter lesions from periventricular (yellow arrows and circles) to
n biopsy analysis of patient #2 showed the reduction of the small
axonal swellings (arrows) larger than 1.5 μm was increased. Scale
Figure 3 Z-score sensory profiles of -10T allele carriers. The Z-score
profile of -10T allele carriers shows a predominant loss of sensory
function in terms of cold and warm hypoesthesia (CDT, WDT, and TSL)
and a reduced mechanical and vibratory sensation (MDT and VDT).
The profile is consistent with a selective small fiber neuropathy in FD.
Negative Z-scores indicate loss of sensation, positive Z-scores indicate
gain of sensation. Error bars represent standard deviation of the mean;
n = 10. CDT: cold detection threshold, WDT: warm detection threshold,
TSL: thermal sensory limen, CPT: cold pain threshold, HPT: heat pain
threshold, PPT: pressure pain threshold, MPT: mechanical pain threshold,
MPS: mechanical pain sensitivity, WUR: wind-up ratio, MDT: mechanical
detection threshold, VDT: vibration detection threshold.
Figure 4 Transmission electron microscopy (TEM) of skin
biopsy of patient #6 (A) and #7 (B). TEM of skin biopsies showed
some endothelia of capillaries with irregular lamellar inclusions (ML).
Mitochondria (M). Nucleus (N). Lumen of the capillary (L). Scale
bar = 500 nm.
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additional diagnostic results did not agree with this
diagnosis. All patients who presented with WML or
stroke/TIA were non-smokers. Except for patients #8
and #12 who presented with well-controlled arterial
hypertension, the remaining patients with stroke/TIA
or WML had normal blood pressure. Only patient #6
was consecutively diagnosed with type 2 diabetes mellitus.
Fabry-typical manifestations such as hypohidrosis, angio-
keratoma, severe gastrointestinal disturbances and tinnitus
were also observed (Additional file 1: Table S1), while only
two patients presented renal manifestations.
In detail, two patients (#12 and #13) suffered from
stroke and three patients (#7, #8, and #10) from TIA
(Table 1). In addition to the index patient, skin biopsies
of three additional patients (#2, #7, and #11) revealed
SFN diagnosed by reduction of IENFD (#1: 4.64/mm, #2:
4.40/mm, #7: 4.65/mm, #11: 3.70/mm; Figure 2D,G), while
the number of focal axonal swelling of intra-epidermal
axons was increased by 20% in patient #2 (Figure 2E,F).
To evaluate the somatosensory phenotype of pain, QST
was performed and was abnormal in 8 patients (#1-4, #7,
and #9-11; Table 1), indicating functional impairment of
A-delta- and C-fibers. In patients #1, #2, #4 and #7 DMA
was present, and patients #3, #7, #9 and #10 had PHS.
The Z-score profile of -10T allele carriers showed a pre-
dominant loss of sensory function in terms of cold and
warm hypoesthesia (CDT, WDT, and TSL) and a reduced
mechanical and vibratory sensation (MDT and VDT), a
profile consistent with a selective small fiber neuropathy
in FD (Figure 3) [27]. Available transmission electron
microscopy of skin biopsies from patients #6 and #7
showed irregular, only partially concentric lamellar
lysosomal inclusions devoid of strictly parallel mem-
branes (Figure 4). Since the -10T haplotype may result
in decreased mRNA expression we performed real-time
PCR analysis revealing decreased mRNA expression
levels in minor T allele carriers. This haplotype resulted
in a significant GLA mRNA expression decrease of 30%
compared to healthy controls (n = 17; p < 0.0001; Figure 5B).
The observed mRNA reduction was associated with
reduced enzymatic GLA activity in three patients (#3,
#11 and #12; Table 2).
Effect of -10T on GLA mRNA expression
As intronic GLA variants such as IVS4+919G>A have been
reported to cause late-onset FD with cardiac phenotype by
altering GLA mRNA processing [7,23], we analyzed the
potential effect of the intronic variants (IVS2-81_-77del-
CAGCC; IVS4-16A>G and IVS6-22C>T) co-segregating
with the -10T allele by exon trapping experiments in an
endothelial cell line (Figure 6). For all investigated intronic
variants neither differences in transcript length nor se-
quence were detected. These observations suggest that theintronic variants IVS2-81_-77, IVS4-16 and IVS6-22 have
no effect on GLA mRNA processing in contrast to the
positive control IVS4+919G>A (Figure 6C). These results
were confirmed in a neuronal cell line (data not shown).
After exclusion of the functional impact of the intronic
variants the reduction of GLA mRNA expression should be
assigned to the -10T promoter allele.
Identification of GLA regulatory promoter regions
Due to the localization of the -10T allele within the GLA
5′-UTR, we investigated GLA promoter transcriptional
activity to identify cis-active regulatory elements. We gener-
ated serial promoter deletion constructs comprising up to
Figure 5 Functional analysis of the -10T allele. (A) Representative chromatograms showing nucleotide substitution at position -10. (B) Carriers
of the minor -10T allele with neurological manifestations (black box; n = 11) showed significantly decreased GLA mRNA expression levels in peripheral
mononuclear blood cells compared to healthy non-carriers (white box; male: n = 8; female: n = 9). (C) GLA expression is significantly decreased in
symptomatic homo-/hemizygous T allele carriers (n = 4) versus symptomatic CT carriers (n = 7). (D) Schematic representation of the GLA 5′-flanking
region. (E) Transient transfection of GLA promoter constructs in EA.hy926 cells revealed two regions with significant transcriptional activity.
(F-H) Insertion of the minor T allele into promoter constructs (black bars) resulted in a decreased transcriptional activity in SH-SY5Y (F), EA.hy926
(G) and THP-1 (H) cells. (I) EMSA with nuclear extract from EA.hy926 cells revealed one specific competable (non-allelic) band (upper arrow) and a
slower migrating T allele-specific band (lower arrow). F: probe without extract and competitor. Data are given as mean ± SEM; LU: light units;
Luc: luciferase.*p < 0.05; ***p < 0.001.
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in the human endothelial cell line EA.hy926. Reporter gene
assays revealed two regions in the GLA 5′-flanking region
with strong transcriptional activity. A proximal region
was located between positions -110 and -425 and a distal
region between -1106 and -1396 (Figure 5E). The region
between -1106 and -425 as well as -4011 and -1396 dis-
played only moderate transcriptional activity. Similar results
were observed in IHKE (kidney epithelial), SH-SY5Y
(neuroblastoma) and THP-1 (monocytic) cell lines (data
not shown).Functional impact of the -10T allele
To investigate the functional impact of the -10T allele on
GLA promoter activity, the -10Tallele was introduced into
the identified transcriptionally active promoter deletion
constructs -425/+104 and -1396/+104 by site-directed
mutagenesis (Figure 5F-H). Within the background of
constructs −425/+104 and −1396/+104 the -10T allele
insertion resulted in a significantly up to 3-fold decreased
transcriptional activity (p < 0.001) in EA.hy926, SH-SY5Yand THP-1 cells. Similar results were observed in IHKE
cells (data not shown).
EMSA experiments with probes resembling the region
containing GLA position −10 resulted in specific binding
patterns with nuclear proteins from EA.hy926 cells. We
identified two specific band shifts, one of which was T
allele-specific (Figure 5I), indicating altered transcription
factor binding in the presence of the -10T allele.
To analyze whether this observation translates into a
dose-dependent reduction of GLA mRNA expression, we
compared hemi/homozygous with heterozygous patients
carrying the 10T allele. Confirming our previous obser-
vations, a significantly reduced GLA mRNA level was
observed in hemi/homozygous patients, indicating a dose-
dependent functional effect of the -10T allele (p < 0.0001;
Figure 5C).
Identification of transcription factor EB (TFEB) as a
regulator of GLA expression
To determine general regulatory factors involved in GLA
expression regulation, we performed in silico analysis.
We identified four putative TFEB binding sites within
Figure 6 Influence of intronic variants on GLA processing. (A) Localization of the intronic variants IVS2-81_-77delCAGCC [rs5903184]),
IVS4-16A>G [rs2071397] and IVS6-22C>T [rs2071228]). (B) GLA exons and denoted flanking introns (wild-type and variant). (C) Agarose gel
separation of exon trapping products. wt: wild-type.
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(Figure 7A). Interestingly, Sardiello et al. [28] described
TFEB as a “master regulator” of lysosomal genes. Subse-
quent overexpression of TFEB and GLA serial promoter
deletion constructs in EA.hy926 cells resulted in a signifi-
cant up to 4.5-fold increased (p < 0.001) transcriptional
activity compared to the vector shuttle control (Figure 7B).
Consequently, TFEB binding site mutation of two highly
conserved binding sites led to total impairment of TFEB
promoter activation (Figure 7B). Since this indicated a
direct interaction of TFEB with the GLA promoter, we
conducted ChIP experiments, which confirmed a specific
interaction of TFEB with region -425 to -239 of the GLA
promoter (Figure 7C).Discussion
Patients suffering from Fabry-typical manifestations with-
out variants in the coding region represent a diagnostic/
therapeutic dilemma as they are usually not treated with
enzyme replacement therapy (ERT). In the current study,
we describe a patient cohort suffering from neurological
manifestations carrying the GLA -10T haplotype, which
has been suggested to be associated with FD in family
studies and case reports [4-6]. To the best of our know-
ledge, the molecular functional basis of the -10T haplo-
type has not been analyzed yet.
Our main findings are: 1) Symptomatic carriers of
the -10T haplotype suffer from neurological manifes-
tations and show decreased GLA mRNA expression
Figure 7 GLA promoter constructs are selectively activated by TFEB. (A) Representation of the four putative TFEB binding sites (underlined)
in the GLA promoter. (B). Overexpression of TFEB in EA.hy926 cells (black bar) compared to mock transfected cells (white bar) and mutagenesis of
conserved TFEB binding sites. (C) ChIP analysis in IHKE cells demonstrated the binding of TFEB. Input: Extracted chromatin served as positive
control for PCR. Data are given as mean ± SEM. LU: light units; Luc: luciferase; ***p < 0.001.
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have no impact on GLA mRNA splicing. 3) The -10T
allele is functionally relevant, leading to a significant
decrease of GLA transcriptional activity as well as T allele-
specific protein-DNA binding. 4) GLA gene expression
depends on the lysosomal “master regulator” TFEB.
Thirteen patients with FD-typical neurological manifesta-
tions such as stroke, TIA, WML and SFN with neuropathic
pain presenting at our Fabry center, had no classical FD-
typical genetic variants, but the -10T haplotype. Recently,
Pisani et al. [5] described a classical FD phenotype in a
young female patient suffering from TIA associated with
the -10T haplotype. In addition, Oliveira et al. [4] reported
that the -10T haplotype was associated with cryptogenic
cerebrovascular small-vessel disease. This genetic combin-
ation was also observed with high frequency (16%) in
patients with SFN of unknown etiology [6]. These individ-
ual reports support our findings that the -10T haplotype
might be associated with neurological manifestations.
Due to the retrospective study design skin biopsies,
cerebral MRI and QST were not available for all patients
of our study cohort. Skin biopsies of four patients out of
five revealed SFN, with typical reduction of IENFD and
focal axonal swelling of intra-epidermal axons. QST
indicated functional impairment of A-delta- and C-fibers
in 80% of the examined patients. All patients diagnosedwith SFN by skin biopsy were also positive in QST ana-
lyses and further examination revealed no evidence for
SFN of other etiologies. Transmission electron microscopy
of two patients (#6 and #7) revealed lysosomal inclusions
representing myelin-like figures, which could be precursors
of FD-pathognomonic zebra bodies. A high proportion
of the patients had reduced GLA mRNA expression
levels, which were associated with reduced GLA enzyme
activity in three patients, two hemizygous males and one
72 year old female patient. Notably, two of these patients
presented WML or stroke as cerebrovascular manifest-
ation. After exclusion of the functional impact of the
co-segregated intronic variants, the observed neurological
manifestations, which might be based on GLA mRNA
expression reduction, may depend on the identified
functional impact of the -10T promoter allele.
Our analysis confirms that the presence of the -10T
allele caused altered transcription factor binding and
reduced GLA promoter transcriptional activity as a
potential cause for the observed reduction of GLA expres-
sion in our patients. Of note, the -10T allele showed a
dose-dependent reduction of GLA expression in our
patients. The observed mRNA reduction translated into
reduced enzymatic GLA activity in three patients when
compared to the reference values and hemi-/homozygous
carriers of the minor T allele in our cohort tended to have
Schelleckes et al. Orphanet Journal of Rare Diseases 2014, 9:178 Page 11 of 13
http://www.ojrd.com/content/9/1/178decreased enzymatic activities compared to heterozygous
T allele carriers. Consistently, previous studies on -10T
allele carriers also reported slightly reduced or normal
GLA activities in plasma or leucocytes [5,6]. Considering
the observed clinical picture of our patients, it seems con-
ceivable that neurological manifestations may occur in
certain, mainly hemi- or homozygous -10T individuals,
while GLA activities in plasma or leucocytes are still in
the reference range.
Of note, plasma lyso-Gb3 levels of our patients were
within the reference range. Lyso-Gb3 is proposed as a
potential biomarker for classical FD phenotypes. The
level of plasma lyso-Gb3 in affected patients is often
higher than in mildly-affected patients [29,30]. Notably,
it has been emphasized that atypical FD variants are often
not associated with increased lyso-Gb3 levels, although
biopsies of affected organs revealed lamellar inclusion
bodies characteristic for FD [31,32]. A FD screening pro-
gram in young patients with cryptogenic ischemic stroke
identified a patient with the -10T haplotype [33]. The
plasma lyso-Gb3 level of this patient was moderately
increased in the first measurement and normal at retest,
suggesting variability of the lyso-Gb3 concentration. These
observations suggest that lyso-Gb3 is of limited use in
FD variants.
The neurological system of FD patients is highly sensitive
to reduced GLA enzyme activity, leading to neuropathic
pain as one of the first symptoms in childhood [34,35].
The potential and possibly mild long-term effect of the
-10T allele on GLA expression might therefore manifest
predominantly in the central and peripheral nervous
system, which seems to be more susceptible to differences
in GLA expression. Lately, other non-classical FD muta-
tions have been described, resulting also in predominantly
neurological manifestations [36,37]. Furthermore, our ob-
servations suggest that the observed neurological pheno-
type might be the result of GLA expression dysregulation
in the presence of the -10T allele and an additional yet
unknown neurological factor. This would explain Fabry-
like disease manifestations even if GLA enzyme activities
are measured within the low normal range. Life-time
exposure to dysregulated GLA expression may thus
lead to neurological manifestations.
A clinical approach with ERT in the index patient
(agalsidase-beta, 1.0 mg/kg BW i.v. every other week,
Fabrazyme, Genzyme) was started in 2006 and cardiac,
renal and neurological examinations as well as biochemical
analyses were performed in yearly follow-ups. ERT led to
clinical stabilization of the FD manifestations, significant
reduction of neuropathic pain, increase of daily activity and
quality of life. Of note, within the first year of therapy the
index patient showed significant pain reduction under ERT
with standard dose of agalsidase-beta (1.0 mg/kg BW i.v.
every other week, Fabrazyme, Genzyme). General diseasestabilization and increased physical activity was also ob-
served. During the worldwide agalsidase-beta shortage and
subsequently dose reduction (0.5 mg/kg BW i.v. every
other week, Fabrazyme, Genzyme) pain increased and daily
physical activity was dramatically reduced due to physical
weakness. This observation is underlined by Weidemann
et al. [38] who reported a significant increase of pain
attacks and crisis under enzyme reduction in a multi-
center study for FD patients. The latter symptoms were
completely restored in the index patient some months after
re-switch to a regular dose of agalsidase-beta.
With respect to our findings, we suggest that patients
carrying the -10T haplotype suffering from typical neuro-
pathic pain and after exclusion of concurrent etiologies
should be treated with established symptomatic medication
(e.g. anticonvulsants blocking calcium channels, anticonvul-
sants and local anesthetics blocking sodium channels, opi-
oids, etc.). In patients with therapy-resistant neuropathic
pain ERT could be an option as shown in our index patient.
Additionally, WML are no primary indication for ERT,
but progression of lesion load should be discussed as
ERT-indication, since ERT has been shown to amelior-
ate endothelial dysfunction in Fabry patients [39-42].
Of note, the frequency of the -10T allele is reported to
be 7% within Caucasian populations [43]. Between 07/2011
and 12/2013, 49 patients, which were diagnosed as classical
Fabry patients by genetic testing, presented at the Fabry
center in Muenster. In the same period, 12 symptomatic
patients were identified as -10T allele carriers without any
further FD-causing mutation. This observation indicates
an estimated incidence of ~1:11,500 symptomatic -10T
allele carriers among all -10T allele carriers.
Conclusions
Based on the presented complementary approach of
clinical data and functional testing, we conclude that in
patients with Fabry-typical neurological manifestations
without coding GLA variants, the -10C>T substitution
could be causal. A limitation of this study is the small
number of patients and the retrospective design. To
evaluate a pathogenic effect of the -10T allele and to
clarify whether patients with the -10T allele and a typical
clinical picture of FD might benefit from ERT for endor-
gan damage prevention, prospective studies with larger
study populations are needed.
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